RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System

Recent advances in the manufacturing, modification, purification, and cellular delivery of ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a broad array of applications. The approval of two SARS-CoV-2-targeting mRNA-based vaccines has highlighted the advances of thi...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 28; no. 18; pp. 3929 - 3939
Main Authors De Mey, Wout, Esprit, Arthur, Thielemans, Kris, Breckpot, Karine, Franceschini, Lorenzo
Format Journal Article
LanguageEnglish
Published United States American Association for Cancer Research 15.09.2022
Subjects
COVID-19 - therapy
Humans
Immune System
Immunotherapy
Neoplasms - genetics
Neoplasms - therapy
Reviews
RNA
SARS-CoV-2 - genetics
Online AccessGet full text

Cover

More Information
Summary:Recent advances in the manufacturing, modification, purification, and cellular delivery of ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a broad array of applications. The approval of two SARS-CoV-2-targeting mRNA-based vaccines has highlighted the advances of this technology. Offering rapid and straightforward manufacturing, clinical safety, and versatility, this paves the way for RNA therapeutics to expand into cancer immunotherapy. Together with ongoing trials on RNA cancer vaccination and cellular therapy, RNA therapeutics could be introduced into clinical practice, possibly stewarding future personalized approaches. In the present review, we discuss recent advances in RNA-based immuno-oncology together with an update on ongoing clinical applications and their current challenges.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Clin Cancer Res 2022;28:3929–39
W. De Mey and A. Esprit share first authorship of this work.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-21-3304